SCHEMBL20876258

SCHEMBL20876258

CCOC(=O)c1cc(C(=O)NC)c2occ(-c3cccc4c3ccn4[Si](C)(C)C(C)(C)C)c2c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ NPSR1 Q6W5P4 3/20 0.33
▸ TP53 P04637 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ ELANE P08246 2/20 0.33
▸ GALR3 O60755 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ GLA P06280 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ NPC1 O15118 2/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ SMN1; SMN2 Q16637 3/20 0.32
▸ CACNA1B Q00975 1/20 0.32
▸ APBA1 Q02410 1/20 0.32
▸ LMNA P02545 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20887348 0.87 POLQ (0.38) MAPTALDH1A1NPSR1TP53TSHR
SCHEMBL22431800 0.85 GALR3 (0.32) MAPTALDH1A1NPSR1TP53TSHR
SCHEMBL20876270 0.77 BRD4 (0.46) —
SCHEMBL20876256 0.76 MEN1 (0.41) MAPTALDH1A1NPSR1TP53TSHR
SCHEMBL20887078 0.74 KDM4E (0.39) GALR3KDM4E
SCHEMBL20887215 0.70 BRD4 (0.41) —
SCHEMBL20876289 0.70 KMT2A (0.42) MAPTALDH1A1NPSR1TP53TSHR
SCHEMBL20887279 0.68 BRD4 (0.43) —
SCHEMBL20887278 0.68 BRD4 (0.43) —
SCHEMBL31176855 0.63 F10 (0.45) MAPTNPSR1ELANEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3692026-B1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS. GLAXOSMITHKLINE IP NO 2 LTD (GB) 2022-07-06 — — EP disclosed
US-11273146-B2 Benzofuran derivatives and their use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2022-03-15 — — US disclosed
US-11273146-B2 Benzofuran derivatives and their use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2022-03-15 — — US disclosed
US-20200289464-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2020-09-17 — — US disclosed
US-20200289464-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2020-09-17 — — US disclosed
EP-3692026-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2020-08-12 — — EP disclosed
WO-2019068783-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289464-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRPF3 MAPT 982/4885ALDH1A1 601/4885NPSR1 2770/4885
US-11273146-B2 Benzofuran derivatives and their use as bromodomain inhibitors BRD4, BRD3, BRPF3 MAPT 982/4885ALDH1A1 601/4885NPSR1 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback